Symbiotec Pharmalab Share Price & Stock Analysis

Quick Answers

What is the Symbiotec Pharmalab share price today? Symbiotec Pharmalab is currently listed and trading. Check our charts for the latest listing performance.

Is Symbiotec Pharmalab a good stock to buy? Review our AI forensic scores and fundamental analysis for Symbiotec Pharmalab to understand the underlying financial health.

Key Stock Information

ViewIPO AI Analysis Score

The Symbiotec Pharmalab Stock scored 56/100 (High Risk) in our deep analysis.

Frequently Asked Questions

What does Symbiotec Pharmalab do?

Symbiotec Pharmalab is a pharmaceutical and biotechnology company that develops and manufactures active pharmaceutical ingredients (APIs), biotechnology products, and complex injectables, and provides CDMO services to pharma and nutraceutical firms.

What are the company’s key product segments?

The company focuses on corticosteroid and steroidal‑hormone APIs, with over 60 products covering hydrocortisone, betamethasone, methylprednisolone, progesterones, estrogens, testosterone, and related molecules.

What is the company’s market position in corticosteroid APIs?

In FY26, Symbiotec held a global volume market share of 38.2% in corticosteroid APIs and 23.8% in steroidal‑hormone APIs, with leading shares in specific molecules such as hydrocortisone (80.1%), testosterone (76.4%) and methylprednisolone (76.0%).

How has the company’s revenue trended over the last three fiscal years?

Revenue increased from ₹716.25 crore in FY24 to ₹751.55 crore in FY25 and ₹869.15 crore in FY26, reflecting steady growth driven by both domestic and international sales.

What proportion of revenue comes from exports?

Export revenue accounted for 59.97% of total revenue in FY24, 55.19% in FY25 and 67.04% in FY26, indicating a growing international footprint.

What are the main uses of the IPO proceeds?

Net proceeds from the fresh issue will be used for prepayment and/or repayment of outstanding borrowings (₹112.5 crore) and for general corporate purposes.

What manufacturing facilities does the company operate?

As of March 31, 2026, the company operates two API manufacturing facilities at Rau and Pithampur, a biomanufacturing facility at Ujjain, and a complex injectables facility at Mhow, all located in Madhya Pradesh.

What regulatory approvals do the company’s facilities have?

The Rau and Pithampur facilities have approvals from the US FDA, EU‑GMP and WHO‑GMP. The company is seeking additional approvals for its new Mhow complex injectables facility.

What are the key risks highlighted in the prospectus?

Key risks include high customer and supplier concentration, geographic concentration of manufacturing in Madhya Pradesh, regulatory compliance risks (including FDA observations), dependence on a limited number of key APIs, foreign exchange and geopolitical exposure, hazardous operations risk, and significant debt levels.

What is the company’s outstanding debt as of March 2026?

As of March 31, 2026, the company had consolidated outstanding borrowings of ₹433.35 crore.

View IPO
View IPO
Home›India›Symbiotec Pharmalab ()
Symbiotec Pharmalab Logo

Symbiotec PharmalabNSE / BSE:

Analyzed by ViewIPO Financial Research Team
PharmaceuticalsIndiaFiled 2026-08-24Listed 2026-09-01Size ₹1757.11Cr
Lot Size 15
Listing Price ₹1173
Listing Return
₹184.95 (+18.72%)
Live Subscription
75.08x Total
Check Allotment
Status Link

Is Symbiotec Pharmalab a Good Stock? Quick Verdict

Symbiotec Pharmalab IPO scored 56/100 (High Risk) in our deep analysis. The strongest pillar is Dilution at 60/100, while Valuation is the primary concern at 50/100. Symbiotec Pharmalab shows strong market leadership in corticosteroid APIs with growing international revenue, but faces high customer and supplier concentration, regulatory risks, and significant debt.

Stock Score
56/100
High Risk

Quick Verdict

Leading global market share of 38.2% in corticosteroid APIs and 23.8% in steroidal‑hormone APIs (FY26).
Revenue grew from ₹716.25 crore in FY24 to ₹869.15 crore in FY26, with export sales contributing 67% of FY26 revenue.
Top 10 customers account for 57‑62% of revenue, creating significant customer concentration risk.
Outstanding borrowings of ₹433.35 crore as of March 2026 indicate a leveraged balance sheet.
Manufacturing facilities are concentrated in Madhya Pradesh, exposing the company to regional operational disruptions.

Company Snapshot

Revenue (TTM)
₹869.15Cr↑ 15.65% YoY
Profitability
—Pending Data
Gross Margin
— 
Market Cap
—Pending Data
Issue Size
₹1757.11Cr 
Industry
Pharmaceuticals 
P/E Ratio
—Pending Data

Risk Breakdown

Governance
60
Moderate
Financial
55
Expensive
Valuation
50
Expensive
Competition
55
Expensive
Dilution
60
Moderate
Promoter / Mgmt
60
Moderate

AI Summary

Symbiotec Pharmalab Ltd is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), biotechnology products, and complex injectables. The company holds leading global market shares in corticosteroid and steroidal‑hormone APIs, with over 60 products in its portfolio and regulatory approvals from the US FDA, EU‑GMP and WHO‑GMP. Revenue increased from ₹716.25 crore in FY24 to ₹869.15 crore in FY26, driven by strong export demand which accounted for 67% of sales in FY26. However, the business is exposed to high customer and supplier concentration, reliance on a single geographic manufacturing base in Madhya Pradesh, and outstanding borrowings of ₹433.35 crore.

Overall Verdict: Symbiotec Pharmalab shows strong market leadership in corticosteroid APIs with growing international revenue, but faces high customer and supplier concentration, regulatory risks, and significant debt.

Key Highlights

  • •Global volume market share of 38.2% in corticosteroid APIs and 23.8% in steroidal‑hormone APIs in FY26.
  • •Portfolio of over 60 corticosteroid and steroidal‑hormone APIs covering ~90% of the market, with 43 US‑FDA DMFs and 23 EDQM CEPs.
  • •Revenue increased from ₹716.25 crore (FY24) to ₹869.15 crore (FY26); export revenue rose to ₹582.64 crore in FY26 (67% of total).
  • •Vertically integrated manufacturing with chemical synthesis capacity of 584.67 MT, fermentation 700 KL, and complex injectable capacity of 20 million vials per annum.
  • •Facilities hold approvals from US FDA, EU‑GMP and WHO‑GMP; three dedicated R&D centres in Indore.
  • •Outstanding borrowings of ₹433.35 crore as of March 2026; debt‑to‑equity not disclosed.
  • •Top 10 customers contributed 57‑62% of revenue in FY24‑FY26; top 10 suppliers accounted for 18‑50% of total expenses, with notable reliance on imports from China.

Financial Performance

Revenue (Annual)

↑ +15.6% YoY

INR in Crores

Net Income (Annual)

Profitability

INR in Crores

EBITDA vs PAT

EBITDA YoY

INR in Crores

EBITDA
PAT
Data not reported in RHP

Listing Timeline

IPO Opens2026-08-24
IPO Closes2026-08-27
Basis of Allotment2026-08-28
Refunds & Demat2026-08-29
Listing Date2026-09-01

Valuation Analysis

Issue Price₹988
Estimated Fair Value
Pending Data
Valuation Premium
Pending
vs Fair Value

Stock DNA

Growth
55
Governance
60
Profitability
55
Valuation
50
Competition
55
Execution
60

Pros vs Cons

Pros

  • Leading global market share in corticosteroid (38.2%) and steroidal‑hormone APIs (23.8%) in FY26.
  • Broad product portfolio of over 60 APIs covering ~90% of the market, supported by 43 US‑FDA DMFs and 23 EDQM CEPs.
  • Strong international presence with export revenue contributing 67% of FY26 sales and customers in over 40 countries.
  • Vertically integrated manufacturing platform enabling backward integration for >80% of revenue‑generating products.
  • Regulatory approvals from US FDA, EU‑GMP and WHO‑GMP for key manufacturing facilities.

Cons

  • High customer concentration: top 10 customers account for 57‑62% of revenue, with no long‑term contracts.
  • Significant supplier concentration: top 10 suppliers represent 18‑50% of total expenses, with notable reliance on imports from China (up to 53% of expenses).
  • Geographic concentration: all manufacturing and R&D facilities are located in Madhya Pradesh, creating regional operational risk.
  • Regulatory risk: FDA Form 483 observations and pending approvals for the new Mhow complex injectables facility.
  • Leveraged balance sheet: outstanding borrowings of ₹433.35 crore as of March 2026.

Financial Health

Revenue Growth
Revenue grew from ₹716.25 crore in FY24 to ₹869.15 crore in FY26 (~21.4% increase over two years). (Good)
Debt Level
Outstanding borrowings of ₹433.35 crore as of March 2026. (Moderate)
Cash & Equivalents
Cash and cash equivalents not disclosed in the prospectus. (Moderate)

Institutional Signals

Anchor Investors
Undisclosed
VC Backing Tier
Undisclosed
Strategic Partners
Undisclosed

Symbiotec Pharmalab IPO Reddit Pulse & Sentiment

Real-time Reddit discussions & retail sentiment

No Public Data Available

We couldn't find any significant public discussions or retail sentiment threads for this IPO at the moment.

Disclaimer: These are raw community discussions aggregated from public forums. The AI summary and Reddit comments do not constitute financial advice. Always conduct your own independent research.

Symbiotec Pharmalab Stock — Frequently Asked Questions

Related Stock Reports

R K Fashion

R K Fashion

RKFAL
55/100
View Report
R

RKFashion Accessories

BSE SME
0/100
View Report
Acme India

Acme India

ACMERAIL
56/100
View Report
Acme India Industries

Acme India Industries

ACMERAIL
54/100
View Report
Paramount Syntex

Paramount Syntex

PARASYNTEX
57/100
View Report
View All Active & Upcoming Stocks & IPOs View Stock & IPO Calendar

Market Terminology Explained

Confused by terms like GMP, Kostak, or Subject to Sauda? Read our detailed guides in the IPO Glossary to understand the terminology before you invest.

Grey Market Premium (GMP)Subject to SaudaASBAOffer for Sale (OFS)
View Full Glossary

Source Citation: All financial data and risk metrics are derived from the official prospectus filed with the regulator (SEBI DRHP/RHP). ViewIPO algorithms process this public data for informational purposes. Not financial advice.

Want to analyze another stock or IPO?

Search any stock, IPO, company, ticker or filing and get instant AI-powered analysis.

Frequently Asked Questions about Symbiotec Pharmalab

What is the expected listing price of Symbiotec Pharmalab?

The expected listing price depends on the live Grey Market Premium. Check the live GMP and expected listing price for Symbiotec Pharmalab on our Live GMP Tracker.